450 related articles for article (PubMed ID: 16365224)
1. Dornase alfa as postoperative therapy in cystic fibrosis sinonasal disease.
Cimmino M; Nardone M; Cavaliere M; Plantulli A; Sepe A; Esposito V; Mazzarella G; Raia V
Arch Otolaryngol Head Neck Surg; 2005 Dec; 131(12):1097-101. PubMed ID: 16365224
[TBL] [Abstract][Full Text] [Related]
2. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities.
Quan JM; Tiddens HA; Sy JP; McKenzie SG; Montgomery MD; Robinson PJ; Wohl ME; Konstan MW;
J Pediatr; 2001 Dec; 139(6):813-20. PubMed ID: 11743506
[TBL] [Abstract][Full Text] [Related]
3. A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis.
Fitzgerald DA; Hilton J; Jepson B; Smith L
Pediatrics; 2005 Oct; 116(4):e549-54. PubMed ID: 16147970
[TBL] [Abstract][Full Text] [Related]
4. Nasally inhaled dornase alfa in the postoperative management of chronic sinusitis due to cystic fibrosis.
Raynor EM; Butler A; Guill M; Bent JP
Arch Otolaryngol Head Neck Surg; 2000 May; 126(5):581-3. PubMed ID: 10807324
[TBL] [Abstract][Full Text] [Related]
5. Sinonasal inhalation of dornase alfa administered by vibrating aerosol to cystic fibrosis patients: a double-blind placebo-controlled cross-over trial.
Mainz JG; Schien C; Schiller I; Schädlich K; Koitschev A; Koitschev C; Riethmüller J; Graepler-Mainka U; Wiedemann B; Beck JF
J Cyst Fibros; 2014 Jul; 13(4):461-70. PubMed ID: 24594542
[TBL] [Abstract][Full Text] [Related]
6. Dornase alfa for cystic fibrosis.
Yang C; Chilvers M; Montgomery M; Nolan SJ
Cochrane Database Syst Rev; 2016 Apr; 4():CD001127. PubMed ID: 27043279
[TBL] [Abstract][Full Text] [Related]
7. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group.
McCoy K; Hamilton S; Johnson C
Chest; 1996 Oct; 110(4):889-95. PubMed ID: 8874241
[TBL] [Abstract][Full Text] [Related]
8. Small airway deposition of dornase alfa during exacerbations in cystic fibrosis; a randomized controlled clinical trial.
Bakker EM; Volpi S; Salonini E; Müllinger B; Kroneberg P; Bakker M; Hop WC; Assael BM; Tiddens HA
Pediatr Pulmonol; 2014 Feb; 49(2):154-61. PubMed ID: 23913868
[TBL] [Abstract][Full Text] [Related]
9. Is a longer time interval between recombinant human deoxyribonuclease (dornase alfa) and chest physiotherapy better? A multi-center, randomized crossover trial.
Wilson CJ; Robbins LJ; Murphy JM; Chang AB
Pediatr Pulmonol; 2007 Dec; 42(12):1110-6. PubMed ID: 17955550
[TBL] [Abstract][Full Text] [Related]
10. Improved treatment response to dornase alfa in cystic fibrosis patients using controlled inhalation.
Bakker EM; Volpi S; Salonini E; van der Wiel-Kooij EC; Sintnicolaas CJ; Hop WC; Assael BM; Merkus PJ; Tiddens HA
Eur Respir J; 2011 Dec; 38(6):1328-35. PubMed ID: 21737560
[TBL] [Abstract][Full Text] [Related]
11. Does the timing of inhaled dornase alfa matter?
van der Giessen L
J Cyst Fibros; 2009 Jun; 8 Suppl 1():S6-9. PubMed ID: 19460684
[TBL] [Abstract][Full Text] [Related]
12. Dornase alfa for cystic fibrosis.
Yang C; Montgomery M
Cochrane Database Syst Rev; 2018 Sep; 9(9):CD001127. PubMed ID: 30187450
[TBL] [Abstract][Full Text] [Related]
13. Dornase alfa improves the health-related quality of life among Brazilian patients with cystic fibrosis--a one-year prospective study.
Rozov T; de Oliveira VZ; Santana MA; Adde FV; Mendes RH; Paschoal IA; Caldeira Reis FJ; Higa LY; Toledo AC; Pahl M;
Pediatr Pulmonol; 2010 Sep; 45(9):874-82. PubMed ID: 20583292
[TBL] [Abstract][Full Text] [Related]
14. Dornase alfa for cystic fibrosis.
Yang C; Montgomery M
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD001127. PubMed ID: 33735508
[TBL] [Abstract][Full Text] [Related]
15. Sinonasal inhalation of dornase alfa in CF: A double-blind placebo-controlled cross-over pilot trial.
Mainz JG; Schiller I; Ritschel C; Mentzel HJ; Riethmüller J; Koitschev A; Schneider G; Beck JF; Wiedemann B
Auris Nasus Larynx; 2011 Apr; 38(2):220-7. PubMed ID: 21030168
[TBL] [Abstract][Full Text] [Related]
16. Dornase alfa: a new option in the management of cystic fibrosis.
Witt DM; Anderson L
Pharmacotherapy; 1996; 16(1):40-8. PubMed ID: 8700791
[TBL] [Abstract][Full Text] [Related]
17. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.
Fuchs HJ; Borowitz DS; Christiansen DH; Morris EM; Nash ML; Ramsey BW; Rosenstein BJ; Smith AL; Wohl ME
N Engl J Med; 1994 Sep; 331(10):637-42. PubMed ID: 7503821
[TBL] [Abstract][Full Text] [Related]
18. Inhaled mannitol for cystic fibrosis.
Nolan SJ; Thornton J; Murray CS; Dwyer T
Cochrane Database Syst Rev; 2015 Oct; (10):CD008649. PubMed ID: 26451533
[TBL] [Abstract][Full Text] [Related]
19. Inhaled mannitol for cystic fibrosis.
Nevitt SJ; Thornton J; Murray CS; Dwyer T
Cochrane Database Syst Rev; 2020 May; 5(5):CD008649. PubMed ID: 32358807
[TBL] [Abstract][Full Text] [Related]
20. Adherence to treatment in children and adolescent patients with cystic fibrosis.
Zindani GN; Streetman DD; Streetman DS; Nasr SZ
J Adolesc Health; 2006 Jan; 38(1):13-7. PubMed ID: 16387243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
